Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Emma Kraynak

Physician Assistant Uniontown, PA Physician Assistant

NPI 1619215894 CMS profile 10789579

650 Cherry Tree Ln, Uniontown, PA 15401

Open in the dashboard

General payments

$9,334

576 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emma Kraynak of Uniontown, PA is reported in the CMS Open Payments database as having received $9,334 across 576 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,328 137
2024 General $2,500 151
2023 General $2,529 157
2022 General $310 22
2021 General $1,667 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emma Kraynak
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Emma Kraynak were reported at $2,328. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Emma Kraynak Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,667 $132 $37–$438 $132
2022 $310 $155 $48–$522 $149
2023 $2,529 $167 $52–$557 $160
2024 $2,500 $178 $55–$600 $164
2025 $2,328 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,071 66 payments
  2. AbbVie, Inc. $972 80 payments
  3. Pfizer Inc. $864 59 payments
  4. GlaxoSmithKline, LLC. $754 47 payments
  5. AstraZeneca Pharmaceuticals LP $734 33 payments
  6. Lilly USA, LLC $661 41 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $583 40 payments
  8. Amgen Inc. $426 27 payments
  9. Exact Sciences Corporation $402 19 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $388 22 payments
  11. Other $2,477 142 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,325 575 payments
  2. Education $9 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $634 55 payments
  2. TRELEGY ELLIPTA $596 38 payments
  3. QULIPTA $589 50 payments
  4. FARXIGA $579 23 payments
  5. MOUNJARO $460 27 payments
  6. ELIQUIS $433 30 payments
  7. NURTEC ODT $426 32 payments
  8. Kerendia $388 22 payments
  9. RYBELSUS $382 23 payments
  10. XARELTO $340 21 payments
  11. Other $7,236 420 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 129 drugs

Part D claims

7,106

Median for Physician Assistant: 241

Drug cost

$1,027,505

Median for Physician Assistant: $4,110

Branded share of claims

22.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 161 $205,430
Eliquis Apixaban Brand 132 $127,222
Mounjaro Tirzepatide Brand 78 $98,741
Jardiance Empagliflozin Brand 79 $96,455
Rybelsus Semaglutide Brand 41 $53,147
Xarelto Rivaroxaban Brand 71 $48,778
Trulicity Dulaglutide Brand 34 $46,889
Tresiba Flextouch U-200 Insulin Degludec Brand 46 $45,206
Farxiga Dapagliflozin Propanediol Brand 22 $27,405
Nurtec Odt Rimegepant Sulfate Brand 16 $23,239

The 10 drugs with the highest cost, of 129 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 41 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $165
$165 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $145
$145 — —
QULIPTA
  • AbbVie, Inc. $128
$128 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $96
  • Lilly USA, LLC $26
$122 79 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $121
$121 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 41 with Patron

Records

576 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record